AngioDynamics (NASDAQ:ANGO) Updates FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of -0.340–0.310 for the period, compared to the consensus EPS estimate of -0.370. The company issued revenue guidance of $285.0 million-$288.0 million, compared to the consensus revenue estimate of $284.9 million. AngioDynamics also updated its FY25 guidance to ($0.34)-($0.31) EPS.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Trading Up 12.4 %

Shares of ANGO opened at $10.86 on Thursday. The firm has a market capitalization of $439.46 million, a price-to-earnings ratio of -1.93 and a beta of 0.56. The firm’s fifty day simple moving average is $10.28 and its 200-day simple moving average is $8.85. AngioDynamics has a twelve month low of $5.47 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) EPS. On average, analysts predict that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.40% of the stock is currently owned by corporate insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.